Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q3 2019 (← Previous) (Next →)

Filing Date: Nov 14, 2019

Total Value ($000): $160,552 (100.0% shares, 0.0% debt)

Holdings (6)

— EYEPOINT PHARMACEUTICALS INC 47.2%

Value ($000) $75,856 Shares 41,909,219 Est. Cost $1.64 Unrealized —

— REVANCE THERAPEUTICS INC 27.1%

Value ($000) $43,447 Shares 3,342,047 Est. Cost $31.50 Unrealized —

AXGN AXOGEN INC 18.9%

Value ($000) $30,326 Shares 2,429,999 Est. Cost $4.01 Unrealized +311.0%

MNOV MEDICINOVA INC 5.9%

Value ($000) $9,539 Shares 1,170,370 Est. Cost $2.95 Unrealized +202.2%

— ENDOLOGIX INC 0.6%

Value ($000) $998 Shares 125,747 Est. Cost $11.05 Unrealized —

— CATALYST BIOSCIENCES INC 0.2%

Value ($000) $386 Shares 78,622 Est. Cost $7.36 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	EYEPOINT PHARMACEUTICALS INC	41,909,219	$75,856	47.2%	$1.64	—	COM	30233G100
—	REVANCE THERAPEUTICS INC	3,342,047	$43,447	27.1%	$31.50	—	COM	761330109
AXGN	AXOGEN INC	2,429,999	$30,326	18.9%	$4.01	+311.0%	COM	05463X106
MNOV	MEDICINOVA INC	1,170,370	$9,539	5.9%	$2.95	+202.2%	COM NEW	58468P206
—	ENDOLOGIX INC	125,747	$998	0.6%	$11.05	—	COM NEW	29266S304
—	CATALYST BIOSCIENCES INC	78,622	$386	0.2%	$7.36	—	COM NEW	14888D208